Prospects for Change at FDA Under the Trump Administration: Early View of What 2017 Will Bring

This webinar will discuss FDA's current priorities and the agency's likely priorities and the future of regulations and policies in 2017 under the new Trump administration.

Why Should You Attend:

The US has a new president, a new Congress, and almost assuredly a new agenda for the FDA - with different policies and priorities than the current administration.

What does this mean for FDA regulated industries?

Steve Grossmann - a long-time D.C. insider, who served as a Senate Health Committee Staff Director and Deputy Assistant Secretary of Health - will discuss what the FDA is doing today and what it likely will be doing under the next administration.

Areas Covered in the Webinar:

After attending this 90-minute webinar you will learn:

• The likelihood that the current commissioner will continue to head the agency - for how long - and who the top candidates are to replace him
• Who will head the FDA transition team and how the process will likely unfold in the next months
• What the FDA’s likely priorities will be in 2017 under the new administration besides the medical device tax and drug pricing and the signals you need to watch for to determine how the new policies will likely impact your company - and your job on a daily basis
• How the new Congress is likely to impact what FDA does in 2017 and whether there will be increased monitoring of specific FDA projects, offices and policies

Who Will Benefit:

Anyone in position to lead an FDA regulated company, new product for regulatory approval or is concerned about trends in FDA regulation and policy will benefit from this webinar.

• Senior Management (C-level, President, VP and Director level)
• Regulatory Affairs
• Product Management
• Consultants
• Attorneys